Physician profile
James Lee
NPI 1437590957
$6,842.41
in general payments reported to CMS, 2019-2025
29 companies · $1,636 in 2025
The $1,636 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $386 · 2021: $702 · 2022: $929 · 2023: $994 · 2024: $2,069 · 2025: $1,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,698.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,768.45 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $952.42 | 2021-2025 | |
| Glaxosmithkline, LLC. | $900.13 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $591.73 | 2019-2024 | Jardiance, Ofev |
| Amgen INC. | $531.35 | 2020-2025 | Repatha, Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $355.53 | 2021-2024 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals Lp | $214.62 | 2021-2025 | Airsupra, Breztri |
| Boston Scientific Corporation | $168.31 | 2021-2022 | |
| Lilly USA, LLC | $162.49 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $140.04 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $125.00 | 2024 | |
| Alnylam Pharmaceuticals INC. | $122.83 | 2023 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $120.29 | 2025 | |
| Merck Sharp & Dohme LLC | $105.59 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Edwards Lifesciences Corporation | $96.47 | 2025 | Sapien 3 Ultra Resilia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $88.60 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $79.58 | 2024-2025 | |
| Exact Sciences Corporation | $77.08 | 2024 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $51.36 | 2024 | Heplisav-B |
| Esperion Therapeutics, INC. | $42.53 | 2024 | Nexletol |
| Renalytix Ai, INC. | $23.85 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $23.68 | 2021 | |
| Almatica Pharma LLC | $18.16 | 2025 | Loreev Xr |
| Ardelyx, INC. | $16.71 | 2024 | Ibsrela |
| Janssen Biotech, INC. | $16.53 | 2024 | Stelara |
| Shield Therapeutics INC | $14.32 | 2025 | |
| Acerus Pharmaceuticals Corporation | $13.28 | 2022 | |
| Genzyme Corporation | $12.37 | 2020 | |
| Pharmaand Gmbh | $9.11 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.